COOPER COMPANIES, INC. (COO)

Sentiment-Signal

8,6

Stark Bearisch

Composite Score (0–100)

Insider (25%)

Keine Insider-Käufe

Institutionell (22,5%)

Keine neuen Positionen

Aktivist (12,5%)

Kein 13D/13G

Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)

Score-Verlauf (90 Tage)

Kritische 8-K Meldungen

Datum	Meldung	Schwere	Filing	Auszug
12.12.2025	Item 5.02 — Abgang Schlüsselpersonen	HOCH	SEC	on 13(a) of the Exchange Act. ☐ Item 5.02. Departure of Directors or Certain Officers: Election of Directors; Appointmen
04.12.2025	Item 5.02 — Abgang Schlüsselpersonen	HOCH	SEC	t forth by specific reference in such a filing. ITEM 5.02. Departure of Directors or Certain Officers; Election of Direc
30.04.2025	Item 5.02 — Abgang Schlüsselpersonen	HOCH	SEC	on 13(a) of the Exchange Act. ☐ Item 5.02. Departure of Directors or Certain Officers: Election of Directors; Appointmen
05.02.2025	Item 5.02 — Abgang Schlüsselpersonen	HOCH	SEC	Section 13(a) of the Exchange Act. ☐ ITEM 5.02. Departure of Directors or Principal Officers; Election of Directors; App
14.12.2023	Item 5.02 — Abgang Schlüsselpersonen	HOCH	SEC	3(a) of the Exchange Act. ☐ Item 5.02. Departure of Directors or Certain Officers: Election of Directors; Appointment of
30.11.2023	Item 5.02 — Abgang Schlüsselpersonen	HOCH	SEC	3(a) of the Exchange Act. ☐ Item 5.02. Departure of Directors or Certain Officers: Election of Directors; Appointment of

Stammdaten

The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment offers spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, myopia, ocular dryness and eye fatigues in the Americas, Europe, Middle East, Africa, and Asia Pacific. The CooperSurgical segment focuses on family and women's health care, which provides medical devices, fertility, genomics, diagnostics, and contraception to health care professionals and patients worldwide. It offers surgical and office products, including PARAGARD, uterine manipulators, retractors, closure products, point of care products, LEEP products, endosee, and illuminate and fetal pillows; fertility products and services, such as fertility consumables and equipment, and embryo options and preimplantation genetic testing. The Cooper Companies, Inc. was founded in 1958 and is headquartered in San Ramon, California.

Unternehmen & Branche

Name	COOPER COMPANIES, INC.
Ticker	COO
CIK	0000711404
Boerse	US
Sektor	Healthcare
Industrie	Medical - Instruments & Supplies
SIC	3851 · Ophthalmic Goods

Wertpapier & Kennzahlen

CUSIP	–
ISIN	–
Typ	Common Stock
Marktkapitalisierung	11,91 Mrd. USD
Beta	1,07
Dividendenrendite	0,00 %

Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »

Finanzkennzahlen (SEC XBRL)

Periode	Filing	Umsatz	Nettoergebnis	EPS	Aktiva	Eigenkapital
2026-01-31	10-Q	1,024,100,000	130,800,000	0.66	12,424,200,000	8,363,800,000
2025-10-31	10-K	4,092,400,000	374,900,000	1.87	12,394,800,000	8,238,900,000
2025-07-31	10-Q	1,060,300,000	98,300,000	0.49	12,376,700,000	8,352,800,000
2025-04-30	10-Q	1,002,300,000	87,700,000	0.44	12,413,600,000	8,287,900,000
2025-01-31	10-Q	964,700,000	104,300,000	0.52	12,222,200,000	8,127,300,000
2024-10-31	10-K	3,895,400,000	392,300,000	1.96	12,315,200,000	8,083,400,000
2024-07-31	10-Q	1,002,800,000	104,700,000	0.52	12,108,000,000	7,925,000,000
2024-04-30	10-Q	942,600,000	88,900,000	0.44	12,047,400,000	7,803,700,000
2024-01-31	10-Q	931,600,000	81,200,000	0.41	12,032,600,000	7,695,100,000
2023-10-31	10-K	3,593,200,000	294,200,000	1.48	11,658,900,000	7,550,800,000
2023-07-31	10-Q	930,200,000	85,300,000	0.43	11,697,300,000	7,528,300,000
2023-04-30	10-Q	877,400,000	39,800,000	0.20	11,539,500,000	7,377,800,000
2023-01-31	10-Q	858,500,000	84,600,000	0.43	11,561,100,000	7,335,500,000
2022-10-31	10-K	3,308,400,000	385,800,000	1.94	11,492,300,000	7,174,500,000
2022-07-31	10-Q	843,400,000	98,400,000	1.98	11,552,100,000	7,082,900,000
2022-04-30	10-Q	829,800,000	126,600,000	2.55	11,778,000,000	7,013,600,000
2022-01-31	10-Q	787,200,000	95,300,000	1.91	11,662,500,000	6,925,900,000
2021-10-31	10-K	2,922,500,000	2,944,700,000	59.16	9,606,200,000	6,941,800,000
2021-07-31	10-Q	763,400,000	615,800,000	12.37	9,610,600,000	6,785,200,000
2021-04-30	10-Q	719,500,000	117,500,000	2.36	9,013,800,000	6,162,600,000

Fondsaktivität (Vorquartalsvergleich)

Keine Fondsdaten für dieses Unternehmen vorhanden.

Insider-Transaktionen (12 Monate)

Datum	Insider	Rolle	Typ	Stückzahl	Kurs	Wert (USD)	Δ
2025-12-22	Lucchese Cynthia L	Director	Open Market Purchase	1,784	84.06	149,963.04	+59,5%
2025-12-18	Rivas Maria	Director	Open Market Purchase	1,000	82.13	82,130.00	+32,6%
2025-12-17	Kurzius Lawrence Erik	Director	Open Market Purchase	2,000	82.50	165,000.00	+65,5%
2025-12-16	Sheffield Holly R	Officer, President, CSI	Open Market Purchase	1,230	80.75	99,322.50	+39,4%
2025-12-16	White Albert G III	Director, Officer, President & CEO	Open Market Purchase	10,000	80.80	808,000.00	+320,5%
2025-09-29	Kurzius Lawrence Erik	Director	Open Market Purchase	2,000	68.39	136,780.00	+54,3%
2025-09-05	Warner Gerard H III	Officer, President, CooperVision, Inc.	Open Market Purchase	1,450	69.23	100,383.50	+39,8%
2025-09-05	White Albert G III	Director, Officer, President & CEO	Open Market Purchase	10,000	68.39	683,900.00	+271,3%
2025-09-02	McBride Daniel G	Officer, EVP & Chief Operating Officer	Open Market Purchase	3,000	65.04	195,120.00	+77,4%
2025-09-02	Andrews Brian G	Officer, EVP, CFO & Treasurer	Open Market Purchase	1,525	65.68	100,162.00	+39,7%

Top-Fondshalter

Keine Fondsdaten zu dieser Aktie vorhanden.